Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study
https://unsplash.com/photos/Y14ONzYtxb4

Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study

  Last year, the FDA placed a clinical hold on an Investigational New Drug (IND) application for deucrictibant for the on-demand and prophylactic treatment of individuals living with hereditary angioedema…

Continue Reading Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study

Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis

Takeda presented encouraging results from the Phase 2b trial (NCT05153148) at the November 2023 American College of Rheumatology (ACR) convergence in San Diego. The Phase 2b study evaluated TYK279 which…

Continue Reading Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis